Lymphoma & Plasma Cell Disorders
From the Journals
Gene expression signature reveals high-grade GCB DLBCL
Patients with this signature had inferior survival outcomes.
News
Priority review granted to lenalidomide for FL, MZL
Celgene is seeking approval for lenalidomide in combination with rituximab to treat previously treated follicular lymphoma or marginal zone...
Conference Coverage
Myeloma therapies raise cardiovascular risks
WASHINGTON – The proteasome inhibitor carfilzomib increases risk for heart failure, and thalidomide analogs increase the risk for venous...
News
Selinexor hits FDA stumbling block
The Oncologic Drugs Advisory Committee expressed concern about the high rate of serious adverse events with the drug being developed to treat...
Conference Coverage
ZUMA-1 update: Axi-cel responses persist at 2 years
HOUSTON – Median duration of response and overall survival have not yet been reached in the pivotal CAR T-cell therapy trial.
Conference Coverage
Dual-targeted CAR T shows ‘clinical signal’ in NHL
HOUSTON – Due to local manufacturing of the CAR T-cell therapy, most patients were able to receive fresh, rather than cryopreserved, product.
Conference Coverage
MRD negativity linked to survival in MM after auto-HCT
HOUSTON – MRD-negative status was prognostic for improved progression-free survival at all time points measured after transplant.
From the Journals
Similar results for once- or twice-weekly carfilzomib in MM
There was no significant difference in safety or survival outcomes among patients with newly diagnosed multiple myeloma.
From the Journals
Alisertib response rate in PTCL patients was 33%
New report explains alisertib’s performance in terminated phase 3 trial.